Checkpoint Therapeutics is an immuno-oncology biopharmaceutical company. It focuses on the development of treatments for patients with solid tumor cancers. The company provides CK-101, a targeted anti-cancer agent for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).